ERBB2 and melanoma: According to many reports indicating that drug resistance is often accompanied by overexpression of receptor tyrosine kinases (RTKs), the expression levels of EGFR, HER2, HER3, MET, and PDGFRβ receptors were verified in both resistant melanoma cell lines.